The [KO Validated] CDKN2A/p16INK4a Monoclonal Antibody (CAB11651) is a high-quality antibody developed for reliable detection and analysis of target proteins. This antibody is validated for use in various applications, including Western blot and immunohistochemistry, and has been shown to have high reactivity with human samples.CDKN2A, also known as p16INK4a, is a tumor suppressor protein that plays a crucial role in regulating cell cycle progression and preventing abnormal cell proliferation. Dysregulation of CDKN2A has been linked to various types of cancer, making it a valuable target for cancer research and potential therapeutic interventions.
This antibody is validated for use in WB, IF/ICC, ELISA applications and has demonstrated reactivity against Human samples.
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
Purification Method
Affinity purification
Gene ID
1029
RRID
AB_2861619
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS containing 50% glycerol and 0.05% BSA, preserved with proclin300 or sodium azide, pH 7.3.
Western blot analysis of lysates from wild type (WT) and CDKN2A/p16INK4a knockout (KO) 293T cells using [KO Validated] CDKN2A/p16INK4a Rabbit mAb (CAB11651) at 1:5000 dilution incubated overnight at 4℃. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25 μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 20s.
Western blot analysis of various lysates using [KO Validated] CDKN2A/p16INK4a Rabbit mAb (CAB11651) at 1:5000 dilution incubated overnight at 4℃. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25 μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 20s.
